184 related articles for article (PubMed ID: 14751469)
1. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram.
Sánchez C; Kreilgaard M
Pharmacol Biochem Behav; 2004 Feb; 77(2):391-8. PubMed ID: 14751469
[TBL] [Abstract][Full Text] [Related]
2. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
[TBL] [Abstract][Full Text] [Related]
3. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
4. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
[TBL] [Abstract][Full Text] [Related]
5. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats.
Mørk A; Kreilgaard M; Sánchez C
Neuropharmacology; 2003 Aug; 45(2):167-73. PubMed ID: 12842122
[TBL] [Abstract][Full Text] [Related]
6. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model.
Sánchez C
Eur J Pharmacol; 2003 Mar; 464(2-3):155-8. PubMed ID: 12620508
[TBL] [Abstract][Full Text] [Related]
7. Protein Kinases Alter the Allosteric Modulation of the Serotonin Transporter In Vivo and In Vitro.
Mnie-Filali O; Lau T; Matthaeus F; Abrial E; Delcourte S; El Mansari M; Pershon A; Schloss P; Sánchez C; Haddjeri N
CNS Neurosci Ther; 2016 Aug; 22(8):691-9. PubMed ID: 27171685
[TBL] [Abstract][Full Text] [Related]
8. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.
Sánchez C; Gruca P; Papp M
Behav Pharmacol; 2003 Sep; 14(5-6):465-70. PubMed ID: 14501259
[TBL] [Abstract][Full Text] [Related]
9. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
10. The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram.
O'Brien FE; O'Connor RM; Clarke G; Donovan MD; Dinan TG; Griffin BT; Cryan JF
Behav Brain Res; 2014 Mar; 261():17-25. PubMed ID: 24280122
[TBL] [Abstract][Full Text] [Related]
11. Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan.
Jacobsen JP; Nielsen EØ; Hummel R; Redrobe JP; Mirza N; Weikop P
Psychopharmacology (Berl); 2008 Aug; 199(2):137-50. PubMed ID: 18496675
[TBL] [Abstract][Full Text] [Related]
12. Micromolar concentrations of citalopram or escitalopram inhibit glycoprotein VI-mediated and integrin αIIbβ3-mediated signaling in human platelets.
Tseng YL; Braun A; Chang JP; Chiang ML; Tseng CY; Chen W
Toxicol Appl Pharmacol; 2019 Feb; 364():106-113. PubMed ID: 30592962
[TBL] [Abstract][Full Text] [Related]
13. Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.
Sánchez C; Hyttel J
Eur J Pharmacol; 1994 Nov; 264(3):241-7. PubMed ID: 7698161
[TBL] [Abstract][Full Text] [Related]
14. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.
Chen F; Larsen MB; Sánchez C; Wiborg O
Eur Neuropsychopharmacol; 2005 Mar; 15(2):193-8. PubMed ID: 15695064
[TBL] [Abstract][Full Text] [Related]
15. The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram.
Arborelius L; Nomikos GG; Hertel P; Salmi P; Grillner P; Höök BB; Hacksell U; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):630-40. PubMed ID: 8738296
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
17. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain.
El Mansari M; Sánchez C; Chouvet G; Renaud B; Haddjeri N
Neuropsychopharmacology; 2005 Jul; 30(7):1269-77. PubMed ID: 15702136
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram versus citalopram: the surprising role of the R-enantiomer.
Sánchez C; Bøgesø KP; Ebert B; Reines EH; Braestrup C
Psychopharmacology (Berl); 2004 Jul; 174(2):163-76. PubMed ID: 15160261
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterisation of the decrease in 5-HT synthesis in the mouse brain evoked by the selective serotonin re-uptake inhibitor citalopram.
Stenfors C; Yu H; Ross SB
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):222-32. PubMed ID: 11218075
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic model of acute autoinhibitory feedback action after administration of SSRIs in rats: application to escitalopram-induced effects on brain serotonin levels.
Bundgaard C; Larsen F; Jørgensen M; Gabrielsson J
Eur J Pharm Sci; 2006 Dec; 29(5):394-404. PubMed ID: 17014998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
